Business Wire

ADVA FSP 3000 TeraFlex™ breaks multiple industry records in live network trial

Share

ADVA (FSE: ADV) today announced that its FSP 3000 TeraFlex™ has broken multiple industry records in a commercial long-haul terrestrial network originally built for 100Gbit/s services. Using an optical spectrum-as-a-service approach, the terminal achieved 200Gbit/s per wavelength transmission over a distance of 5,738km with 2.5bit/symbol, and 500Gbit/s over 1,016km with 5bit/symbol modulation. The ADVA FSP 3000 TeraFlex™ is the first commercially available solution to achieve such results. One of the keys to its success here was its ability to utilize network telemetry and fractional QAM to maximize reach and capacity through the automated configuration of modulation format and baud rate. Conducted with ADVA’s partners, the Poznan Supercomputing and Networking Center (PSNC), EENet of HITSA and Tele2 Estonia, the trial also highlighted how a disaggregated open line system (OLS) approach can enhance network flexibility and leverage the most value from existing optical infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190724005055/en/

The record-breaking ADVA FSP 3000 TeraFlex™ scores multiple industry firsts (Photo: Business Wire)

The record-breaking ADVA FSP 3000 TeraFlex™ scores multiple industry firsts (Photo: Business Wire)

“Our terminal technology is now redefining terrestrial long-haul data transport. Just as we proved in trials with DCI and metro networks, the software-defined transmission of our FSP 3000 TeraFlex™ is the ultimate response to soaring bandwidth needs,” said Jörg-Peter Elbers, SVP, advanced technology, ADVA. “With its programmable signal shaping and ultra-flexible modulation capabilities, our unique solution balances distance and capacity for maximum spectrum utilization and optimal performance over any reach. This gives communication service providers the power to massively increase bandwidth without the expense of a major upgrade. This demo also shows how an open coherent optical layer removes all restrictions, even when interconnecting across multiple countries. And, with our FSP 3000 TeraFlex™ deployed as part of a disaggregated OLS solution, it delivers complete agility for best cost efficiency.”

Using the Baltic Highway between Tallinn, Estonia and Frankfurt, Germany, operated by Tele2 Estonia, the trial set a series of new benchmarks for bandwidth and reach on terrestrial long-haul networks. Record-breaking results also included 300Gbit/s per wavelength transmission over 3,751km with 3bit/symbol, and 400Gbit/s per wavelength across 1,792km with 4.5bit/symbol modulation. Feasibility of 800Gbit/s transmission over 1,016km in a single 125GHz spectral slice was also demonstrated. The ADVA FSP 3000 TeraFlex™ retrieves optical channel conditions via network telemetry. It can then determine the best possible capacity and spectral occupation for each light path. This is a key advantage for network operators seeking to best exploit untapped capacity in their existing infrastructure without the cost of a complete system upgrade or overbuild.

“We’re seeing huge demand for capacity in crucial backbone links like our Baltic Highway. This demo responds to that fierce growth by enabling new levels of capacity and best spectral efficiency. It offers a way to tackle huge increases in traffic volume while also making major savings and increasing overall operational simplicity,” commented Ove Ant, director, carrier and enterprise sales, Tele2 Estonia. “Using our coherent open optical layer with flexgrid ROADMs, which is also built on ADVA FSP 3000 technology, the demo highlights how much more value can be squeezed out of long-haul networks. With the power to automate the reconfiguration of modulation and baud rate for different reaches and spectrum service parameters, the ADVA FSP 3000 TeraFlex™ is a genuine game changer.”

“This demo has great significance for the national research and education network (NREN) community. It shows how the enormous data demands of high-performance computing and international site-to-site connectivity can be addressed with ultra-flexible spectrum services,” said Artur Binczewski, director, network technology division, PSNC. “Openness and automated modulation adjustment will be key to meeting the challenges of tomorrow’s NRENs. Alongside ADVA, EEnet of HITSA and Tele2, we’re showing how the capacity of deployed infrastructure can be massively increased, enabling networks like ours to support scientists and academics with more bandwidth-intensive applications than ever before. This will enable us to continue advancing academic discourse, bolstering the economy and keeping Europe at the forefront of global learning and research.”

Further information on this record-breaking trial can be found in these slides: http://adva.li/teraflex-tele2-trial.

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.

Published by:

ADVA Optical Networking SE, Munich, Germany

www.advaoptical.com

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing